Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;97(5):1498-1502.
doi: 10.4269/ajtmh.17-0094. Epub 2017 Oct 10.

Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India

Krishna Pandey  1 , Biplab Pal  2 , Niyamat Ali Siddiqui  3 , Vidya Nand Rabi Das  1 , Krishna Murti  2 , Chandra Shekhar Lal  4 , Neena Verma  5 , Rajendra Babu  2 , Vahab Ali  4 , Rakesh Kumar  1 , Pradeep Das  6
Affiliations

Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India

Krishna Pandey et al. Am J Trop Med Hyg. 2017 Nov.

Abstract

Liposomal amphotericin B is being used increasingly to reduce the burden of kala-azar from the Indian subcontinent. There are studies which have evaluated efficacy and safety of liposomal amphotericin B for visceral leishmaniasis in all age groups. However, the only study that specifically addressed treatment of childhood visceral leishmaniasis did not include all ages or document renal and liver function. We, therefore, felt it was important to reassess the efficacy and safety of single dose liposomal amphotericin B in children and adolescents. A total of 100 parasitologically confirmed visceral leishmaniasis patients aged < 15 years were included in this study. Participants consisted of 65 males and 35 females. All of them had come from the endemic region of Bihar. They were administered one dose intravenous infusion of liposomal amphptericin B at 10 mg/kg body weight. Efficacy was assessed as initial and final cure at 1 and 6 months, respectively, and safety of all participants who were recruited in the study. The initial and final cure rate by per protocol analysis was 100% and 97.9%, respectively. Chills and rigors were the most commonly occurring adverse events (AEs). All the AEs were mild in intensity, and none of the patients experienced any serious AEs. No patients developed nephrotoxicity. Our finding indicates that liposomal amphotericin B at 10 mg/kg body weight is safe and effective in children. Results of our study support the use of single dose liposomal amphotericin B in all age group populations for elimination of kala-azar from the Indian subcontinent.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patients disposition.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671. - PMC - PubMed
    1. Sundar S, Chatterjee M, 2006. Visceral leishmaniasis—current therapeutic modalities. Indian J Med Res 123: 345–352. - PubMed
    1. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM, 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3: 87–98. - PubMed
    1. Thakur CP, Narayan S, Ranjan A, 2004. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 120: 166–172. - PubMed
    1. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J, 2012. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543–550. - PubMed

LinkOut - more resources